Festivities will be hosted at the beautiful Ciel Social Club atop AC Hotel in Downtown DC

In 2020, approximately 604,000 women were diagnosed with cervical cancer (CxCa), and 342,000 women died. Nearly 90% of CxCa-associated deaths occur in low- and middle-income countries (LMICs), where access to health services including screening and treatment remains limited. The World Health Organization (WHO) developed a global strategy to eliminate CxCa as a public health problem, which could result in >62 million lives saved by 2120. Strategy targets by 2030 include: 90% of adolescent girls receiving prophylactic HPV vaccine, 70% of women receiving twice-lifetime CxCa screening, and 90% of lesions treated. However, implementation lags behind strategy targets. The cost and complexity of HPV screening and treatment approaches may hamper scale-up, particularly for LMICs. Development of therapeutic HPV vaccines (TxV), designed to clear persistent high-risk HPV infection and/or cause CIN lesion regression, could aid in cervical cancer elimination. The potential value of TxV is highest if they can be developed and implemented quickly in addition to ongoing scale-up of existing interventions. To understand the full potential value of these vaccines, it is important to consider how they would be used and delivered within broader CxCa prevention programs, as well as the vaccine attributes that would optimize their public health impact. This 90-minute session will explore the potential for TxV to meet the global public health need, by reducing CxCa cases and deaths. Participants will gain an understanding of the potential public health value, scientific feasibility, future implementation considerations, and WHO preferred product characteristics.

Learning Objectives: After participating in this session, attendees should be able to: 1. Describe the current state of knowledge on HPV screening, prevention, and treatment for people living with HIV 2. Evaluate current screening, vaccination, and treatment recommendations for people living with HIV based on up-to-date research findings 3. Discuss further research needs on this topic for people living with HIV Duration: 90 minutes

The global HPV laboratory network (LabNet) was organized by the WHO in 2007 to promote the quality-assured laboratory services required for HPV DNA and antibody detection. A large number of countries officially appointed National HPV Reference Laboratories (NRL) and in 2021 the Global Network of National HPV Reference Laboratories was formed to continue promoting the quality-assured HPV testing services that will be required for optimal HPV and cervical cancer elimination strategies. The purpose of this satellite symposium with participation of NRLs from Australia, Japan, Turkey, Belgium, France, Germany, Scotland, Slovenia, South Africa, Sweden, Norway, USA, and Argentina is to report on activities and exchange scientific and practical information. The tentative topics are: (1) NRL re-analysis of HPV-negative high-grade cervical lesions as a means to further testing quality; (2) key performance indicators for HPV-based screening (3) joint resources for furthering HPV testing quality: global proficiency panels; E-learning resources and (4) role of reference laboratories to further HPV elimination. The symposium is open to all laboratories interested in HPV testing, with the hope that the support from the NRLs can be increasingly effective for contributing to advancement of HPV testing services.